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Abstract
BACKGROUND: The aim of this study was to observe and characterize the nonspecific 18F-choline lymph node uptake in 
patients with prostate cancer. 
MATERIAL AND METHODS: In this single center, prospective observational study which was done in University Hospital Cen-
ter Zagreb between December 2012 and October 2014, 69 patients (median age 71 years; range 50–92) with prostate cancer 
were included. Patients underwent 18F-choline PET/CT for staging or restaging of prostate cancer. The mean follow-up period 
was 11.5 months. Kruskal-Wallis test was used to find out if the differences between SUV values of specific and nonspecific 
accumulation of the tracer are statistically significant.
RESULTS: Nonspecific accumulation of 18F-choline in lymph nodes was found in 36 patients (52.7%). Most of these findings 
(n = 24) were nonspecific accumulation of the tracer in mediastinal lymph nodes. Other sites of nonspecific tracer uptake were 
pulmonary hila (n = 20), inguinal lymph nodes (n = 15), and axillary lymph nodes (n = 10). Mean SUV values for mediastinal 
lymph nodes, pulmonary hila, axillary and inguinal lymph nodes were 4.8, 4.3, 3.1 and 4.1, respectively. Mean SUV value of 
nonspecific sites of tracer accumulation was lower (not significantly; (p = 0.2) than tracer uptake values measured in metastases 
sites (bone metastases mean SUVmax value — 13.2, metastatic lymph nodes mean SUVmax value — 9.2).
CONCLUSIONS: 18F-choline PET/CT is a valuable and an established functional diagnostic imaging method for staging and 
restaging prostate cancer. However, nonspecific uptake of the tracer can often be seen in lymph nodes not related to primary 
disease. Patient history, clinical examination, laboratory tests and correlation with other imaging methods, must be taken into 
consideration when interpreting 18F-choline PET/CT findings.
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Background
Prostate cancer is the most common malignancy in men in 
Europe and the US [1, 2]. Diagnostic procedure from clinical sus-
picion to diagnosis includes determination of PSA serum value, 
transrectal ultrasound (TRUS) with or without biopsy, magnetic 
resonance imaging (MRI), computerized tomography (CT) and 
bone scintigraphy in patients with highly elevated PSA values [3–5]. 
Defining the Gleason score, evaluating local disease extent, 
locoregional lymph node involvement and presence of distant 
metastases is crucial in patient management and deciding on 
correct follow-up modality. Increasing demands for correct disease 
characterization and extent, as well as variable biological behavior 
of prostate cancer, have led to the extensive use of functional 
imaging, positron emission tomography coupled with computed 
tomography (PET/CT). PET/CT imaging is most often used as a re-
staging modality, especially after completed primary radiotherapy or 
radical prostatectomy followed by an increase of PSA levels [6, 7]. 
Because of prostate cancer low avidity for the currently most used 
radiopharmaceutical, 18F-fluorodeoxyglucose (18F-FDG), as well 
as its urinary tract elimination and accumulation in the urinary blad-
der, other radiopharmaceuticals have been developed. In use today 
are 18F and 11C-labeled choline and 11C-acetate. In growing tumor 
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tissue, increased lipid synthesis is found, as well as the increased 
activity of choline kinase enzyme activity which increases choline 
uptake. On the cell level imported choline becomes part of the cell 
membrane, as phosphatidylcholine [8]. Physiological tracer uptake 
is found in the liver and pancreas, spleen, salivary and lachrymal 
glands. Variable uptake can be present in the bone marrow, the 
small and large intestines kidneys, urinary bladder and ureters [9]. 
18F-choline has been recognized as a valuable imaging method 
for prostate cancer evaluation, notably after primary treatment 
has been done [10–12]. As with each diagnostic tool, apart from 
all the benefits and relevant data it provides, some drawbacks have 
been noticed. Nonspecific uptake of 18F-choline is seen in lymph 
nodes, whether a low-grade lymphoma or, more often, inflammatory 
altered inguinal, axillary or mediastinal lymph nodes, as has been 
reported by some scientific groups [9, 13].
The purpose of this study was to observe and characterize 
nonspecific lymph node uptake of 18F-choline in order to expand 
the awareness of broader physiological 18F-choline uptake.
Material and methods
Design and setting
This prospective observational study was done in University 
Hospital Center Zagreb from December 2012 till October 2014.
Participants
Sixty nine patients underwent 18F-choline PET/CT for staging 
or restaging of their disease. The patients have been referred from 
their oncologists mostly because of increased PSA values observed 
after primary therapy.
Their median age was 71 years, range 50–92 years. The me-
dian PSA value was 5.3 ng/ml (doubling time less than 6 months in 
9 patients). PSA values exceeding 0.2 ng/ml for patients with radi-
cal prostatectomy and 2 ng/ml higher than the lowest known PSA 
value for patients with only radiotherapy treatment were considered 
as biochemical relapse. PSA values that doubled in less than 
6 months previous to PET/CT scan and the increase of 1 ng/ml of 
prostate specific antigen over the past year were also considered 
as clinically relevant. In 38 patients radical prostatectomy was per-
formed, 18 of which had received hormonal therapy. Twenty three 
patients underwent radiotherapy, and in 12 it had followed radical 
prostatectomy. Thirty four patients have received hormonal therapy, 
while 13 patients received no therapy before 18F-choline PET/CT 
examination (Table 1).
18F-choline PET/CT examination
All patients fasted 6 hours before the examination. Mean 
administered activity was 183 MBq (4.9 mCi) of 18F-choline 
(2 MBq/kg, IASOcholine was purchased from IASON GmbH A-8054 
Graz-Seiersberg, Austria). The whole-body PET/CT was acquired 
20 minutes after the intravenous F-choline administration (Sie-
mens Biograph mCT, Siemens Medical Solutions USA, Inc., USA 
PET/CT; 3 minutes per bed position).
The follow-up was at least 6 months, median 11, range 
6–22 months.
Interpretation of 18F-FDG PET/CT scans
All PET/CT scans were interpreted by two board-certified nu-
clear medicine physicians (DH, AM). An increased uptake was de-
fined as focal activity higher than that of surrounding background 
tissue not located in areas of physiological 18F-choline uptake, 
without similar activity seen on the contralateral side. SUV value 
was calculated for each lesion. A normal uptake was defined as no 
abnormal 18F-choline uptake.
As true positive were considered patients with clearly visible 
increased uptake in the lymph nodes or bone structures in the 
regions where prostatic cancer metastases can be often found 
(pelvis, central skeleton). Those patients received further treatment 
(most often radiotherapy or hormonal therapy) suggested by their 
referring physicians.
Reference standard
In patients with increased tracer uptake in easily reachable 
lymph nodes a fine needle aspiration cytology (FNAC) or biopsy 
was performed. A true negative finding was noted if the FNAC or 
biopsy analysis reported a benign lesion or the follow-up period 
was at least 6 months without any disease progression observed.
Ethics
Signed informed consent was obtained from all patients for 
imaging and using patient data for further research.
Statistical analyses
Kruskal-Wallis test was used to determine differences between 
SUV values of specific and nonspecific accumulation of the tracer.
Results
Specific accumulation of the tracer
True positive focal uptake in prostate bed (local recurrence) 
was found in 6 (9%) patients, with a mean SUVmax value of 10.2. 
Bone metastases were found in 15 patients (21.7%; SUVmax mean 
value 13.2, range 4.7–21.3). True positive findings in the abdominal, 
retroperitoneal (Figure 1) and iliac lymph nodes were noted in 27 
patients (39.1%, SUVmax mean value 9.2, range 3.9–16.1) (Table 2). 
Pulmonary metastases have been observed in two patients with 
the SUVmax values of 6.8 and 2.3. All of our patients with positive 
findings and tracer uptake in abdominal lymph nodes, bone and 
lung metastases were scheduled for subsequent treatment, mostly 
radiotherapy.
Nonspecific accumulation of the tracer
Nonspecific tracer uptake to the lymph nodes was observed in 
36 patients (52.7%). Most of the false-positive lymph nodes were 
identified in the mediastinum (24 patients; mean SUVmax value 
of 4.8) (Figure 2), and pulmonary hila (20 patients, mean SUVmax 
Table 1. Prostate cancer patient population therapy modalities before 
18F-choline PET/CT exam
Procedures performed Patients (n = 69)
Radical prostatectomy (RP) 38 (55.1%)
Radiotherapy (RT) with or without RP 23 (33.3%)
Hormonotherapy with or without RP and RT 34 (49.3%)
Orchidectomy 10 (14.5%)
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values of 4.3). The uptake in axillary lymph nodes was found in 10 pa-
tients with a mean SUVmax value of 3 and in inguinal lymph nodes in 
15 patients (Figure 3), with mean SUVmax value of 4.1 (Table 3).
Median PSA value in patients with nonspecific tracer uptake 
was 5.8, while it was found to be 8.8 in patients with 18F-choline true 
positive lesion (not statistically significant, p = 0.2).
Additional ultrasound examination with fine needle aspiration 
cytology of available lymph nodes was performed in 5 patients; 
4 were found to have nonspecific inguinal lymph nodes enlarge-
ment where cytological analysis showed only fatty tissue or cystic 
contents, while in one a relapse of CLL lymphoma was observed.
Mean SUV value of the sites of nonspecific accumulation of the 
tracer (mean 4.1) was not statistically significantly lower (p = 0.2) 
than tracer uptake values measured in metastases sites (mean 11.2).
Discussion
Results of this study showed that in over half of our patient 
population, nonspecific sites of tracer uptake have been observed 
in lymph nodes out of the pelvis, not suggestive for prostate cancer 
metastases. The obtained SUV values in those uptake sites were 
lower than in metastatic sites, but not enough to be statistically 
significant. In most cases, we have observed accumulation of 
18F-choline in the mediastinal lymph nodes (35% of patients). The 
main limitation of our study is that pathohistological confirmation 
has not been performed, but during patient follow-up there have 
been no evidence of disease progression, rise in PSA levels or 
patient deaths due to prostate cancer. Additional ultrasound exami-
Figure 1. Retroperitoneal lymph node metastasis in the pelvis in 
patients with prostate cancer. SUVmax value 10.2, PSA value 0.5 
ng/ml, radical prostatectomy performed in December 2013, imaged 
in April 2014. Radiotherapy and hormonal therapy followed PET/CT 
examination; SUV — standardized uptake value, PSA — prostate-
specific antigen
Figure 2. Nonspecific 18F-choline uptake in mediastinal lymph nodes 
in patients with prostate cancer, SUVmax 8.8, PSA value 2.3 ng/ml. 
Patient had radical prostatectomy in November 2010, and was imaged 
in our facility in February 2014; SUV — standardized uptake value, 
PSA — prostate-specific antigen
Table 2. 18F-choline true positive focal lesions
Location Patients 
(n = 35)
Mean SUVmax 
value
Prostate bed (local recurrence) 6 (8.7%) 10.2
Bone metastases 15 (21.8) 13.2
Abdominal lymph node metastases 27 (39.1%) 9.2
SUV — standardized uptake value
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nation with fine needle aspiration cytology of axillary and inguinal 
lymph nodes with low tracer uptake has shown fatty infiltration in 
four patients and a relapse of low grade lymphoma in one patient. 
No similar false positive, nonspecific radiotracer uptake was found 
in abdominal or pelvic lymph nodes, making the interpretation 
easier. In the minimal 6 month follow-up (median of 11.5 months), 
no clinically apparent sign of disease progression was found, 
pertaining to patients with nonspecific lymph node uptake. Other 
limitations of this study were relatively small sample size and clus-
tering patients with variable disease stages and treatment options. 
Also, in patients with very suggestive findings for prostate cancer 
metastases (local recurrence in pelvis, central skeleton) we didn’t 
obtained final pathology confirmation since referring physicians or-
dered a further therapy without any delay.
Variability in physiological distribution, pitfalls and image arti-
facts of F-18-FDG has been the topic of numerous articles [14, 15], 
and the same considerations should be made when imaging with 
18F-choline.
Up to date only one study (Rietbergen et al [13]) reported similar 
percentage of patients with nonspecific choline uptake, not pertain-
ing to prostate cancer disease extent. Liu et al [16] have shown 
increased choline uptake in various thoracic diseases, such as sar-
coidosis, noncaseating granuloma, tuberculosis and lymphomas.
18F-choline accumulation is found to be specific in true positive 
lesions with a prevailing morphological and statistical correlate. 
Nonspecific tracer uptake will follow an increased cell membrane 
production not connected to prostate cancer, but rather due to 
acute or chronic inflammatory process or low grade immunopro-
liferative diseases.
18F-choline PET/CT is considered a particularly useful diagnostic 
tool in several stages of patient care, with the added information 
gained from revealing multiple pathophysiological processes. It 
has found its role especially in restaging prostate cancer patients, 
with the recommended use in patients with PSA levels > 1 ng/ml 
following radical disease treatment [6]. Increasing demands of 
imaging modalities have been observed in recent years because 
of aging population, screening methods and growing incidence 
of prostate cancer.
The need for unequivocal disease extent estimation has intro-
duced functional imaging methods, such as 18F-choline PET/CT, 
in regular clinical practice [17], and the future of prostate cancer 
imaging will lie in the more specific radiotracers, such as the PSMA 
tracer [18–20].
Conclusions
Although 18F-choline PET/CT has demonstrated valuable 
information in staging and restaging of prostate cancer, moder-
ate tracer accumulation in lymph nodes out of the pelvis should 
be carefully evaluated since in many cases it is false positive. 
Variability in physiological uptake, as well as benign causes of 
accumulation, such as inflammation, should be kept in mind when 
interpreting unusual sites of increased uptake, with no association 
with the primary disease. Recognizing the importance of patient 
follow-up is crucial.
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